INTRODUCTION
Small cell lung carcinoma (SCLC) is an aggressive neuroendocrine neoplasia, which is strongly related to smoking attitude, characterized by rapid growth and very poor overall survival, usually diagnosed as a central tumor. 1 It accounts for 13-15% of all lung cancers and represents the sixth most common cause of death for malignant tumours. 2 Histological evaluation is mandatory. According to the World Health Organization (WHO), morphology and immunohistochemistry should be performed for the final diagnosis. 3 The lack of specific symptoms at early tumor stages and the lack of screening methods continue to be the main obstacles for the early detection of this disease. Most patients are diagnosed with advanced diseaseoften with a metastatic dissemination (extensive stage [ES] ). 4 Because of the highly progressed disease states, clinical courses are usually too short to identify the causes, resulting in multi-organ failure.
We describe the unusual case of an occult SCLC with clinical onset for jaundice and fulminant progression up to death within a few days. The particularities of the case are also its incidental diagnosis at autopsy, clinical onset with non-obstructive jaundice liver disease, and the rapid progression towards death.
To date 35 cases (in 25 papers) of SCLCs with diffuse liver metastases and fulminant liver failure have been described in the medical literature, but in 9 cases the clinical onset was sudden and without warning, followed by a quick death.
We will carry out a critical review of all published cases.
CASE REPORT
A 78-year-old male, who was a heavy smoker, presented at the Emergency Department with recently appeared jaundice (sclera and skin) and lower limbs edema. Past medical history included chronic obstructive pulmonary disease and hypertensive heart disease. He had no history of hepatitis, alcohol abuse, or drug allergy. On admission, the physical examination revealed a globose abdomen with marked hepatomegaly, respiratory examination was consistent with chronic bronchitis with mild dyspnea and shortness of breath.
A n a b d o m i n a l a n d t h o r a c i c c o m p u t e d tomography was performed and showed a lesion in the lower lobe of the right lung highly suspicious of malignancy, and marked hepatomegaly not otherwise specified.
Due to severe renal, cardiac, and hepatic conditions, the patient was hospitalized in intensive care. The patient developed hepatic encephalopathy and later went into a coma. He died with acute liver failure (ALF) and multi-organ failure only 7 days after admission.
AUTOPSY PRESENTATION

The Autopsy Revealed Unexpected Findings
The liver (Figure 1 ) extended from the right to the left hipochondrium.
The liver's dimensions had increased so much that it could be measured from the costal arch of 14 cm on the right and 6 cm on the left. The liver weighed 4.25 kg (Reference range [RR]; 1.5 kg) and the cut surface was entirely occupied by small yellowish-white nodules of varying sizes (average size of 0.3-0.4 cm). Moderate ascitic fluid (approx. 400 mL) was present. There was evidence of bilateral pulmonary edema, and lower limbs edema. In the right lower pulmonary lobe ( Figure 2 ) there was a yellowishwhite nodule of 5.5 cm, which involved bronchial branches. There were bilateral lymphadenopathies; the ipsilateral major lymph node measured 1.9 cm. The left ventricle hypertrophy (wall thickness of the left ventricle of 2.3 cm) was compatible with hypertensive heart disease. No brain lesions were identified and the other organs did not show remarkable changes. The liver was enlarged due to massive SLCL infiltration, which was also responsible by the cholestasis (Figures 4 and 5) . No signs of portal hypertension was found. The spleen was small (weighed 70g, mean RR; 112g), and was histologically normal.
The Remaining Organs Were Free of Neoplastic Infiltration
Based on the gross and microscopic features and the clinical picture, the cause of the patient's death might therefore be placed as: "ALF and multi-organic damage associated with the hepato-renal syndrome in SCLC with massive hepatic infiltration."
DISCUSSION
Most studies regarding fulminant hepatic failure in metastatic liver SCLC have been published as case reports. To our knowledge, in 25 scientific papers a total of 35 cases of hepatic failure due to metastatic SCLC were reported (see Table 1 ).
An autopsy was performed in 24 of the 35 published cases. Apart from our case, only 10 others have been described with sudden onset and death within a few days. In 8 of these 10 cases, an autopsy was performed. In this type of case, performing an autopsy is of paramount importance to understand the causes of death. Let us consider these eight cases and compare them with ours.
The lung tumors (when measured) in these cases were large, from a minimum of 14 mm 29 to a maximum of 48 mm; 26 in our case it measured 55 mm and was the largest ever described, yet it remained clinically silent.
In the other 35 reported cases, the liver weight ranged between 1.4 and 8.2 kg; 21, 27 in our case, the liver weighed 4.25 kg.
In the other cases, death occurred after a minimum of 1 hour 22 from the time of arrival in the hospital to D = days; E = enlarged; EM = extensive metastases; F = female; H = hepatomegaly; M = male; ME = moderately enlarged; NA = not available; S = sudden; SCLC = small cell lung carcinoma; y = year.
a maximum of 14 days 5 (average of 7.1 days); in our case death occurred 7 days after hospitalization.
The liver is the most common site for metastatic tumor deposits with evidence of hepatic metastases reported in 36% of all patients who died from cancer. 30 Despite this, liver dysfunction may not be evident. Fulminant hepatic failure (FHF; also known as ALF) secondary to a metastatic tumor is rare. In some cases, tumors may replace up to 90% of the liver without any manifestation of jaundice. However drowsiness and abdominal pain have been reported.
Small cell lung cancer is so highly invasive that hepatic metastasis is common, but a rapid progression to ALF is extremely rare. In most patients with ALF secondary to malignant infiltration of the liver, the prognosis is terrible.
In cases of very rapid progression from the time of clinical onset, the cause of hepatomegaly may be unknown at the time of the patient's death.
CONCLUSION
Each case of ALF of undetermined etiology must be evaluated with a high index of suspicion. The aggressiveness of SCLC is well documented and, in many cases, metastatic lesions are diagnosed prior to the discovery of the primary tumor. In hepatomegaly, imaging is often non-diagnostic. In order to suggest which therapies to follow, liver biopsy must be considered in indeterminate cases.
Diffuse liver metastasis must be considered when imaging modalities show hepatomegaly in patients with FHF, especially when viral hepatitis and drug reactions are excluded. It is therefore of paramount importance for the clinician to take hepatomegaly into consideration in the investigation of distant metastases of unknown primary origin.
The role of the autopsy in this type of case is fundamental.
